Profile - To The Moon

ETCH

Posts · 27Posts · 27
Following · 0Following · 0
Followers · 0Followers · 0

- ETCHETCH
  ·2021-09-10
  Time is running out for market share
  Why Novavax Stock Slipped Thursday
  (Update: Sept 10, 2021 at 04:14 a.m. ET) Authorization of the company's COVID-19 vaccine in India a
  Why Novavax Stock Slipped Thursday
  6.95K 1
  7
  Share
  Report
- ETCHETCH
  ·2021-08-24
  Great
  Cybersecurity Awareness Drive Hits Changhai County's Commercial Hub
  To advance the 2026 National Cybersecurity Awareness Week campaign under the theme "Cybersecurity for the People, Cybersecurity by the People — Smart Era, Cyber Protection," the Changhai County...
  Cybersecurity Awareness Drive Hits Changhai County's Commercial Hub
  4.32K Comment
  3
  Share
  Report
- ETCHETCH
  ·2021-08-11
  X, CLF, NUE, AA.. all the materials stock ready toboom on this deal
  Sorry, this post has been deleted
  6.73K 3
  6
  Share
  Report
- ETCHETCH
  ·2021-08-09
  Ok
  Sorry, this post has been deleted
  5.34K Comment
  2
  Share
  Report
- ETCHETCH
  ·2021-08-06
  Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed
  Sorry, this post has been deleted
  6.55K 1
  3
  Share
  Report
- ETCHETCH
  ·2021-08-04
  Pfizer slow and steady NVAX roller coaster rideChoose your poison
  3 COVID Stocks That Could Soar Higher
  Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021. Key Points Pfi
  3 COVID Stocks That Could Soar Higher
  5.45K Comment
  8
  Share
  Report
- ETCHETCH
  ·2021-08-01
  ok well
  Sorry, this post has been deleted
  5.60K Comment
  5
  Share
  Report
- ETCHETCH
  ·2021-07-30
  Inflation rate keep climbing.. correction soon..
  Sorry, this post has been deleted
  5.31K Comment
  3
  Share
  Report
- ETCHETCH
  ·2021-07-29
  Buy index and sleep well at night
  Sorry, this post has been deleted
  7.55K 2
  5
  Share
  Report
- ETCHETCH
  ·2021-07-26
  Nice
  Lockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate
  Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same
  Lockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate
  5.28K Comment
  Like
  Share
  Report
No following yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3576835084140349","uuid":"3576835084140349","gmtCreate":1613741215736,"gmtModify":1704447500967,"name":"ETCH","pinyin":"etch","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":17,"tweetSize":27,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.83%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":883490547,"gmtCreate":1631261575289,"gmtModify":1676530512000,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Time is running out for market share","listText":"Time is running out for market share","text":"Time is running out for market share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883490547","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://ttm.financial/m/news/1158877090?lang=en_US&edition=fundamental","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p>\n<blockquote>\n <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>\n <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>\n <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p>\n<p><b>So what</b></p>\n<p>SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p>\n<p>The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p>\n<p>This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p>\n<p><b>Now what</b></p>\n<p>Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p>\n<p>Novavax fell over 2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 15:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":6953,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835449547,"gmtCreate":1629734905889,"gmtModify":1676530116979,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835449547","repostId":"1189910879","repostType":4,"repost":{"id":"1189910879","kind":"news","weMediaInfo":{"introduction":"Global Stock Market Deep Analysis","home_visible":1,"media_name":"Deep News","id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"pubTimestamp":1789974072,"share":"https://ttm.financial/m/news/1189910879?lang=en_US&edition=fundamental","pubTime":"2026-09-21 15:01","market":"sg","language":"en","title":"Cybersecurity Awareness Drive Hits Changhai County's Commercial Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=1189910879","media":"Deep News","summary":"To advance the 2026 National Cybersecurity Awareness Week campaign under the theme \"Cybersecurity for the People, Cybersecurity by the People — Smart Era, Cyber Protection,\" the Changhai County...","content":"<p>To advance the 2026 National Cybersecurity Awareness Week campaign under the theme \"Cybersecurity for the People, Cybersecurity by the People — Smart Era, Cyber Protection,\" the Changhai County Cyberspace Affairs Office, together with the county's Public Security Bureau Cyber Security Brigade and the three major telecom operators — China Mobile, China Unicom, and China Telecom — recently held a centralized awareness event in front of the Lianhua Supermarket on the commercial street.<br><br>At the event, staff set up consultation booths, displayed banners, and distributed informational brochures to educate passersby on national security knowledge, personal information protection, and guarding against online rumors, while also answering questions on the spot. Over 1,000 promotional materials were distributed during the day, reaching a hundred or more residents and bringing cybersecurity knowledge directly to the community.<br><br>The interactive format of face-to-face communication and immediate Q&A made cybersecurity information more relatable and accessible to everyday life. Many residents paused to seek advice, and through the staff's patient explanations, they gained a deeper understanding of how to protect personal data and prevent the spread of online misinformation.<br><br>This concentrated campaign serves as a key component of the county's broader Cybersecurity Awareness Week activities. Moving forward, Changhai County plans to focus on vulnerable groups such as the elderly and teenagers, delivering targeted science-based outreach to encourage safe internet habits, promote resistance to rumor-spreading, and safeguard personal information — together building a strong line of defense for nationwide cybersecurity awareness.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cybersecurity Awareness Drive Hits Changhai County's Commercial Hub</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCybersecurity Awareness Drive Hits Changhai County's Commercial Hub\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-21 15:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>To advance the 2026 National Cybersecurity Awareness Week campaign under the theme \"Cybersecurity for the People, Cybersecurity by the People — Smart Era, Cyber Protection,\" the Changhai County Cyberspace Affairs Office, together with the county's Public Security Bureau Cyber Security Brigade and the three major telecom operators — China Mobile, China Unicom, and China Telecom — recently held a centralized awareness event in front of the Lianhua Supermarket on the commercial street.<br><br>At the event, staff set up consultation booths, displayed banners, and distributed informational brochures to educate passersby on national security knowledge, personal information protection, and guarding against online rumors, while also answering questions on the spot. Over 1,000 promotional materials were distributed during the day, reaching a hundred or more residents and bringing cybersecurity knowledge directly to the community.<br><br>The interactive format of face-to-face communication and immediate Q&A made cybersecurity information more relatable and accessible to everyday life. Many residents paused to seek advice, and through the staff's patient explanations, they gained a deeper understanding of how to protect personal data and prevent the spread of online misinformation.<br><br>This concentrated campaign serves as a key component of the county's broader Cybersecurity Awareness Week activities. Moving forward, Changhai County plans to focus on vulnerable groups such as the elderly and teenagers, delivering targeted science-based outreach to encourage safe internet habits, promote resistance to rumor-spreading, and safeguard personal information — together building a strong line of defense for nationwide cybersecurity awareness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4588":"碎股","HAKY":"Amplify HACK Cybersecurity Covered Call ETF","NSI":"NATIONAL SECURITY EMERGING MARKETS INDEX ETF","NBDS":"Neuberger Disrupters ETF","BCTK":"Baron Technology ETF","FDIF":"Fidelity Disruptors ETF","CRWL":"2倍做多CRWD ETF-GraniteShares","LOUP":"Innovator Deepwater Frontier Tech ETF","INVN":"Alger Russell Innovation ETF","USMD":"CoreValues America First Technology ETF","PSWD":"XTRACKERS CYBERSECURITY SELECT EQUITY ETF","PSCT":"小盘科技股ETF-PowerShares","SKYY":"First Trust Cloud Computing ETF","SPAM":"THEMES CYBERSECURITY ETF","CIBR":"First Trust NASDAQ Cybersecurity ETF","DRES":"GMO Domestic Resilience ETF","TEK":"iShares Technology Opportunities Active ETF","WCBR":"WisdomTree Cybersecurity Fund","XT":"iShares Exponential Technologies ETF","EIS":"iShares MSCI Israel ETF","IHAK":"iShares Cybersecurity and Tech ETF","FDFF":"Fidelity Disruptive Finance ETF","FITE":"SPDR Kensho Future Security ETF","FWD":"AB DISRUPTORS ETF","MVPS":"Amplify Thematic All-Stars ETF","TEKX":"SPDR Galaxy Transformative Tech Accelerators ETF","KOMP":"SPDR S&P Kensho New Economies Composite ETF","BK4585":"ETF&股票定投概念","TEKY":"Lazard Next Gen Technologies ETF","GSFP":"Goldman Sachs Future Planet Equity ETF","ANEW":"ProShares MSCI Transformational Changes ETF","CRTC":"XTRACKERS US NATIONAL CRITICAL TECHNOLOGIES ETF","UCYB":"ProShares Ultra Nasdaq Cybersecurity ETF","BUG":"Global X Cybersecurity ETF","CRWC":"Corgi CRWD 2x Daily ETF","BPAY":"iShares FinTech Active ETF"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189910879","content_text":"To advance the 2026 National Cybersecurity Awareness Week campaign under the theme \"Cybersecurity for the People, Cybersecurity by the People — Smart Era, Cyber Protection,\" the Changhai County Cyberspace Affairs Office, together with the county's Public Security Bureau Cyber Security Brigade and the three major telecom operators — China Mobile, China Unicom, and China Telecom — recently held a centralized awareness event in front of the Lianhua Supermarket on the commercial street.At the event, staff set up consultation booths, displayed banners, and distributed informational brochures to educate passersby on national security knowledge, personal information protection, and guarding against online rumors, while also answering questions on the spot. Over 1,000 promotional materials were distributed during the day, reaching a hundred or more residents and bringing cybersecurity knowledge directly to the community.The interactive format of face-to-face communication and immediate Q&A made cybersecurity information more relatable and accessible to everyday life. Many residents paused to seek advice, and through the staff's patient explanations, they gained a deeper understanding of how to protect personal data and prevent the spread of online misinformation.This concentrated campaign serves as a key component of the county's broader Cybersecurity Awareness Week activities. Moving forward, Changhai County plans to focus on vulnerable groups such as the elderly and teenagers, delivering targeted science-based outreach to encourage safe internet habits, promote resistance to rumor-spreading, and safeguard personal information — together building a strong line of defense for nationwide cybersecurity awareness.","news_type":1,"symbols_score_info":{"FITE":1,"BPAY":1,"BUG":1,"GSFP":1,"NBDS":1,"TEK":1,"FWD":1,"TEKY":1,"BCTK":1,"FDIF":1,"PSWD":1,"KOMP":1,"PSCT":1,"EIS":1,"HAKY":1,"NSI":1,"CRWL":1,"WCBR":1,"SKYY":1,"LOUP":1,"CRWC":1,"MVPS":1,"XT":1,"CRTC":1,"INVN":1,"IHAK":1,"DRES":1,"TEKX":1,"ANEW":1,"FDFF":1,"UCYB":1,"CIBR":1,"USMD":1,"SPAM":1}},"isVote":1,"tweetType":1,"viewCount":4319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892174124,"gmtCreate":1628646190368,"gmtModify":1676529807235,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","listText":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","text":"X, CLF, NUE, AA.. all the materials stock ready toboom on this deal","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/892174124","repostId":"1185123318","repostType":4,"isVote":1,"tweetType":1,"viewCount":6728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898725902,"gmtCreate":1628523372606,"gmtModify":1703507608186,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898725902","repostId":"2158442754","repostType":4,"isVote":1,"tweetType":1,"viewCount":5335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893382601,"gmtCreate":1628238268103,"gmtModify":1703503738908,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed","listText":"Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed","text":"Submitted EUA in India, Indonesia and PhilippinesThose are the markets where vaccine are needed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/893382601","repostId":"1103242546","repostType":4,"isVote":1,"tweetType":1,"viewCount":6551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890001411,"gmtCreate":1628064152233,"gmtModify":1703500523823,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Pfizer slow and steady&nbsp;NVAX roller coaster rideChoose your poison&nbsp;","listText":"Pfizer slow and steady&nbsp;NVAX roller coaster rideChoose your poison&nbsp;","text":"Pfizer slow and steady NVAX roller coaster rideChoose your poison","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890001411","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://ttm.financial/m/news/1124757232?lang=en_US&edition=fundamental","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Pfizer might surprise to the upside.</li>\n <li>Inari Medical is growing like gangbusters.</li>\n <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li>\n</ul>\n<p>COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p>\n<p>A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<h3><b>Pfizer: More room to run</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p>\n<p>Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p>\n<p>There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p>\n<p>Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p>\n<p>The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p>\n<p>Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p>\n<h3><b>Inari Medical: Skyrocketing Sales</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p>\n<p>This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p>\n<p>Not to mention the company's results thus far for blood clots in the lung are spectacular:</p>\n<ul>\n <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>\n <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>\n <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>\n <li>No ICU stays are required after the procedure.</li>\n</ul>\n<p>Add it all up, and Inari's retrieval device seems like an obvious choice.</p>\n<p>The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p>\n<p>Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p>\n<h3><b>Novavax: How high can it go?</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p>\n<p>Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p>\n<p>Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p>\n<p>In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p>\n<p>Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 10:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1,"symbols_score_info":{"NARI":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":5449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802787592,"gmtCreate":1627808771416,"gmtModify":1703496165724,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"ok well","listText":"ok well","text":"ok well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/802787592","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":5595,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806612256,"gmtCreate":1627653325275,"gmtModify":1703494180907,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Inflation rate keep climbing.. correction soon..&nbsp;","listText":"Inflation rate keep climbing.. correction soon..&nbsp;","text":"Inflation rate keep climbing.. correction soon..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806612256","repostId":"1109167679","repostType":4,"isVote":1,"tweetType":1,"viewCount":5309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801174817,"gmtCreate":1627493155939,"gmtModify":1703491117846,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Buy index and sleep well at night&nbsp;","listText":"Buy index and sleep well at night&nbsp;","text":"Buy index and sleep well at night","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/801174817","repostId":"2154918711","repostType":4,"isVote":1,"tweetType":1,"viewCount":7547,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3564210269929975","authorId":"3564210269929975","name":"kk__soh","avatar":"https://static.tigerbbs.com/f54f0205e29fd09d7864877ae54901e3","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3564210269929975","idStr":"3564210269929975"},"content":"Help me like if not I will go jail","text":"Help me like if not I will go jail","html":"Help me like if not I will go jail"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800665278,"gmtCreate":1627299121894,"gmtModify":1703487053811,"author":{"id":"3576835084140349","authorId":"3576835084140349","name":"ETCH","avatar":"https://static.tigerbbs.com/2f1ff4cf08fc7dbd87a3a3322be433e9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576835084140349","idStr":"3576835084140349"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/800665278","repostId":"2154570979","repostType":2,"repost":{"id":"2154570979","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627299058,"share":"https://ttm.financial/m/news/2154570979?lang=en_US&edition=fundamental","pubTime":"2021-07-26 19:30","market":"us","language":"en","title":"Lockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2154570979","media":"Benzinga Earnings","summary":"Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same","content":"<html><body><p>Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same period last year.  The company reported quarterly sales of $16.26 billion which missed the analyst consensus estimate of $16.33 billion by 0.44 percent.  This is a 3.88 percent increase over sales of $15.65 billion the same period last year.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLockheed Martin Q1 EPS $6.56 Beats $6.30 Estimate, Sales $16.26B Miss $16.33B Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2021-07-26 19:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same period last year.  The company reported quarterly sales of $16.26 billion which missed the analyst consensus estimate of $16.33 billion by 0.44 percent.  This is a 3.88 percent increase over sales of $15.65 billion the same period last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMT":"洛克希德马丁"},"source_url":"https://www.benzinga.com/news/earnings/21/07/22144945/lockheed-martin-q1-eps-6-56-beats-6-30-estimate-sales-16-26b-miss-16-33b-estimate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154570979","content_text":"Lockheed Martin (NYSE:LMT) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.30 by 4.13 percent. This is a 7.89 percent increase over earnings of $6.08 per share from the same period last year.  The company reported quarterly sales of $16.26 billion which missed the analyst consensus estimate of $16.33 billion by 0.44 percent.  This is a 3.88 percent increase over sales of $15.65 billion the same period last year.","news_type":1,"symbols_score_info":{"LMT":1}},"isVote":1,"tweetType":1,"viewCount":5275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}